Atomwise, co-founded by Next Founders alum Abraham Heifets, which uses deep learning to shorten the process of discovering new drugs, has raised a $45 million Series A. The round was led by Monsanto Growth Ventures, Data Collective (DCVC) and B Capital Group. Baidu Ventures, Tencent and Dolby Family Ventures, which are all new investors in Atomwise, also participated, as well as returning investors Y Combinator, Khosla Ventures and DFJ.
This means Atomwise, which was founded in 2012, has now raised more than $51 million in funding. The company, which aims to reduce the amount of money and time researchers spend on finding compounds for medications, says it now has more than 50 molecular discovery programs. Atomwise’s technology is also being used to develop safer, more effective agricultural pesticides.Read More